|Day Low/High||80.88 / 82.43|
|52 Wk Low/High||69.18 / 99.84|
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
These are the 10 reasons why we keep going up, despite all the bad news.
We're seeing lots of companies snapping up their peers, and the market is applauding.
Let's check in on this Swiss-based pharmaceutical giant.
There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.
These stocks are priced for total imperfection. That's just what you want.
On the biggest day for earnings reports in the S&P let me give you my scorecard to date so you know which pile your stocks might land in.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.
The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
We've got some push-pull in pre-market trading as moves lower in Netflix , Limelight Networks , United Rentals , SAP and Alcoa duel with Apple , which is moving higher pre-market, and positive moves in Novartis , eBay , Phillip Morris International ...
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Let's review the charts and indicators this morning.
Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
If we can advance without China then who the heck knows where we can go with it.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
CBD could make coffee an around the clock craze.